New 8-Week Treatment Approved for All Hepatitis C Genotypes — Physician’s First Watch

August 7, 2017

New 8-Week Treatment Approved for All Hepatitis C Genotypes

By Kelly Young

Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH

The FDA has approved the first 8-week treatment for chronic hepatitis C genotypes 1 through 6 in patients with mild or no cirrhosis.

Mavyret, a combination of glecaprevir and pibrentasvir, is also approved for patients with renal impairment and adults with HCV genotype 1 infection who've been treated with either an NS5A inhibitor or an NS3/4A protease inhibitor.

In clinical trials, 92-100% of patients treated with Mavyret for 8, 12, or 16 weeks had no detectable viral levels 12 weeks post-treatment.

Common adverse reactions included fatigue, headache, and nausea. Clinicians should screen patients for prior or current hepatitis B infection before starting treatment as some coinfected patients have reported HBV reactivation after taking HCV direct-acting antivirals.

Mavyret is contraindicated in patients with severe cirrhosis and those taking atazanavir and rifampin.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.